Inovio (INO) Q2 FY26 earnings call

Inovio is nearing a critical juncture with its lead candidate, INO-3107, for RRP, as the BLA review progresses towards an October PDUFA date. The company has strengthened its financial position to support a potential launch, while also advancing its broader pipeline through strategic partnerships. Management remains focused on addressing the significant unmet need in RRP with a differentiated product profile, despite the FDA's ongoing review of accelerated approval eligibility.